RANTES plays a crucial role in cell recruitment in allergic inflammation. We investigated the pharmacological modulation of RANTES release in cultured peripheral blood mononuclear cells obtained from allergic patients with active asthma. Chemokine production was assessed before and after 15 day treatment with histamine-I receptor antagonists (Loratadine or Cetirizine) and a steroid (Deflazacort), both in unstimulated and PHA-stimulated cell cultures. Results were compared with those obtained from placebo-treated patients. During the treatment period, patients recorded morning and evening peak expiratory flow (PEF) by mini-Wright.
antihistamines have been demonstrated to be able to affect cellular activation, adhesion molecule expression and mediator release during allergic inflammation (8, 9) .
Taking into consideration the central role of RANTES in the maintenance of allergic inflammation (l 0,11), the modulation of its expression may represent an important therapeutic target.
The aim of the study was to evaluate modulation ofRANTES release from cultured peripheral blood mononuclear cells (PBMCs), obtained from allergic patients with active asthma, by antiallergic drugs. Chemokine production was assessed before and after 15 day treatment with antihistamines (loratadine and cetirizine) and steroid (deflazacort"), both in unstimulated and PHA-stimulated cell cultures. Results were compared with those obtained in the same experimental conditions from placebotreated patients.
MATERIALS AND METHODS
Eighteen asthmatic patients (18 -42 years old, non smokers) allergic to Parietariajudaica, referring to the out-patient clinic of the Allergy and Clinical Immunology Unit of Chieti Medical School Hospital, were enrolled in May during the active period of pollination. Sensitization to Parietaria was established by skin test (Allergopharma, Hamburg, Germany) and specific IgE (Pharmacia, Uppsala, Sweden). Patients were affected by moderate persistent asthma (12) from 3-6 years with symptoms during spring and summer. They were enrolled after a 30-day period of wash-out from anti-inflammatory treatment and randomly assigned to antihistamine, steroid or placebo treatment. Six patients were treated by deflazacort per os (12 mg/day) (Group A), twelve by antihistamines (Group B), in particular six by cetirizine (10 mg/day) (Group B I) and six by loratadine (10 mgt day) (Group B2) ( Table 1) and six with placebo (Group C). During wash-out and treatment periods, no others drugs, other than salbutamol (as needed) were allowed. Every day during the treatment period patients recorded morning and evening peak expiratory flow (PEF) by mini-Wright (Markos, Milan, Italy).
Cell cultures
Peripheral heparinized whole blood was collected from each patient before and after treatment.. Blood was diluted 1:1 with 0.9% NaCI solution. The PBMCs were isolated with Fycoll-Hypaque (Pharmacia, Uppsala, Sweden) and mononuclear cells were collected at the interface, washed twice in RPMI 1640 medium (Gibco, Milan, Italy) and then suspended at 10 6 cells/ml in complete medium: RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum (FCS-Sigma Chern co, St Louis, MO), 2 mM L-glutamine and 100U/ml penicyllin/streptomycin. Cells were cultured in polypropylene tubes at a density 1 x 10 6 cells/ml and maintained in a 5% CO 2 incubator, at 37°C for different time periods, and the viability was determined by trypan blue exclusion (>99%). Cultures were set up in duplicate, with and without phytohaemagglutinin (PHA). At the end of the culture period, cells were centrifuged and supernatants stored at -70°C until analysed.
RANTES production from PBMC was evaluated after 24 hour cultures, when maximum release of RANTES is observed (10) .
ELISA of RANTES in PBMC supernatants
Antigenic RANTES in PBMC supernatants was quantified using a solid phase sandwich ELISA for humanRANTES (Endogen, Woburn, U.S.A.). RANTES was also quantified in serum of all patients. Assays were performed exactly as recommended by the manufacturer.
Statistical Analysis
All analyses were performed using the S-Plus 2000 program. Continuous variables are reported as mean±Standard Error (S.E.). Systematic differences between the two antihistamine treatments -Loratadine and Cetirizine -were tested using the non-parametric Mann-Whitney U test; moreover systematic differences between the three treatment -deflazacort, antihistamines and placebo -were evaluated using one-way analysis of variance; post hoc analyses were performed using Student-Newman-Keuls t test.
Confirmatory non-parametric Kruskal Wallis analyses were also performed; nevertheless, no gross difference with the parametric test was detected.
Robust Regression models were performed to analyse the efficacy of the three treatments on RANTES release and to exclude the statistical effect of basal RANTES level, in PHA-stimulated and unstimulated cultures. Statistical significant level was fixed at p ::;; 0.05.
RESULTS
All patients treated with steroids and antihistamines showed a symptomatic improvement. However, PEF absolute values and diurnal variability significantly improved, respect to those before therapy in steroid-treated patients, compared to the placebo and antihistamine groups (p<O.OI and 0.001, respectively). However, PEF diurnal variability in group B was lower than in group C, but this did not reach statistical significance (p=0.06). (Fig 1) .
No differences could be found in RANTES levels in PBMC culture supernatants before and after treatments, both in PHA-stimulated and unstimulated cultures form patients treated with the two antihistamines (loratadine and cetirizine). Therefore, we considered them as one antihistamine group comprising both drugs (group B) (Tab. 2). Table 3 shows the mean values and S.E. of RANTES release in supernatants of un-stimulated and PHA-stimulated cultures of all groups, before and after treatment.
Before treatment, a significant difference in RANTES levels was found between the four groups. In detail, RANTES levels detected in unstimulated cultures from anti-histamine treated patients were significantly higher than those from steroid and placebo groups (p=0.004). On the contrary, in PHA-stimulated cultures RANTES levels were significantly higher in group A than in group B and C (p=0.004). After 15 days of therapy, RANTES levels were significantly lower in steroid treated patients than in groups Band C, both in unstimulated (p=0,008) and in PHA-stimulated cultures (p=0,02).
RANTES release in supernatants of both PHAstimulated and unstimulated cultures of BPMCs from group A and group B was significantly reduced after treatment with respect to the basal values (figs 2 and 3), whereas, it was slightly increased in group C (p=NS).
Considering the pre-treatment levels of RANTES release, robust regression models were also applied to analyse the efficacy of the different treatments in RANTES release inhibition, avoiding any statistical effect of basal RANTES level.
Co-variance analysis of RANTES levels, adjusting for pre-treatment values, showed a significant reduction of RANTES release in PHAstimulated cultured PBMCs from steroid (p=0,003) and anti-histamine (p=0,03) groups, respect to the placebo group (tab 4 a). Robust regression models applied between steroid and antihistamine groups showed the lowest levels of RANTES associated with steroid treatment (tab 4 a), also in this case reaching statistical significance (p=0,005), considering basal levels of this chemokine.
The same statistical tool, adopted for studying RANTES levels in PHA-unstimulated cultures, did not show any significant difference among the three groups (tab 4 b).
DISCUSSION
The presented evidences show that steroids and antihistamines are both effective in inhibiting RANTES release form cultured PBMCs of atopic patients. Indeed, RANTES levels in supernatants of cultured PBMCs were substantially reduced after either treatment compared to the levels detected before therapy (Figs 2 and 3) . RANTES modulation is clearly evident in all cultures, even though it is easier recognizable in PHA-stimulated cells (Tabs 3 and 4).
Additionally, our study confirms that steroids are more effective than antihistamines in inhibiting RANTES release. However, antihistamines also induced a decrease in chemokine release, significantly more than placebo. On the contrary, RANTES levels in supernatants ofcultured PBMCs did not significantly change after treatment in placebo treated patients.
RANTES, as well as other chemokines, such as eotaxin I and II, MCP-3 and MCP4 (13) plays a critical role in beginning and in maintaining allergic inflammation, as it is a chemotactic agent for eosinophils and basophils. Inflammatory cells must be primed by cytokines to heighten their responsiveness, interact with vascular endothelium, and migrate into tissues where they degranulate and characterize the late phase reactions of allergy.
Several studies have shown that RANTES has a central role in bronchial inflammation, by increasing haptotaxis activity mainly on eosinophils, RANTES, along with MIP-Ict induces exocytosis of eosinophil cationic protein from cytochalasin-B treated cells (14) . When injected into the skin of dogs RANTES induces an infiltration ofeosinophils and monocytes (15) . RANTES is able to recruit mast cells (4) and it has a role on stimulation of other inflammatory cells at inflamed sites (16) . These activities subsequently co-operate in inducing a persistence of inflammation.
Inflammatory cells, recruited into tissues where allergic inflammation occurs, may perpetuate the inflammatory response by virtue of their local activation and secretion. Although antigen may be present to activate the cell, activation by chemokines can occur in the absence of antigen and the presence of IgE antibody is no longer necessary (17) . The present finding that shows steroids can significantly decrease the release of RANTES from cultured PBMCs underlines the importance of steroid treatment of allergic diseases, and confirms previous studies. In particular, it has been shown that dexamethasone dramatically inhibits RANTES mRNA expression in human PBMCs and in T cells (18) , corticosteroids downregulate synthesis and/ or release of RANTES from bronchial epithelial cells (19, 20) and topical fluticasone inhibits allergen induced increase in the production/release of chemokines (21) .
In our study, steroids appeared more effective than antihistamines, considering RANTES inhibition both in unstimulated and in PHAstimulated PBMC cultures (Tab 3). However, evaluating the difference in pre-treatment levels of RANTES, a statistically significant reduction was evident only in PHA-stimulated cultures (tab 4).
Steroids are essential in the treatment of chronic phases of allergic disease, but their systemic administration sometimes brings out important side effects. This evidence urges research to find drugs with an anti-inflammatory activity such as steroids, but deprived of its side effects.
Interestingly, both Loratadine and Cetirizine have shown an antinflammatory effect in our experiments, inducing a significant reduction of RANTES release by PBMC cultures (p=0,03). After both antihistamine treatments, RANTES release in supernatants of PBMCs was lower than in the placebo group, with a significant reduction in the PHA-stimulated cultures. No significant differences were found between the two antihistamines (tab 2).
Some authors reported that RANTES injected intradermally into both allergic and non allergic subjects accelerates eosinophil recruitment only in allergic subjects; whereas no eosinophil infiltrate was observed in non-allergic subjects (6, 14) . This observation provides support for the hypothesis that eosinophils from these subjects are primed in vivo, and that RANTES plays an important role in allergic diseases along with other mediators such as Th2-like cytokines (9, 17) , and over-expressed adhesion molecules (22) .
Recent studies have shown antihistamines, in addition to the well-known antagonistic activity on HI receptors, have a direct anti-inflammatory activity capable of affecting several aspects of the allergic inflammation, including mediator release, cellular activation and adhesion molecule expression (23, 24) . Cetirizine and Loratadine are able to control minimal persistent inflammation, characterized by ICAM-l over-expression (25) (26) (27) , and they have a similar effect in modulating nasal epithelial cell ICAM-l expression (26) Trypton cells.
RANTES is associated with an inflammatory response characterized by enhanced production of chemokines, inflammatory mediators and celluler accumulation and activation (29, 30) . During the allergic response, there is a marked induction of specific chemokines that are involved in the recruitment and activation of cells that contribute to the orchestration of the inflammatory process (7, 30, 31) .
Recently, it has been reported that RANTES may participate in airway inflammation by interacting with both Thl and Th2 derived cytokines to modulate chemoattractant activity foreosinophils, activated T lymphocytes and monocyte/macrophages, and by enhancing IgE production induced by IL-4 (32) (33) .
Taking into consideration the central role of this cytokine and chemokine network and of adhesion molecules in inducing an inflammatory response in allergic diseases, the use of long term therapy with anti-histamines togethe with specific immunotherapy (34) may induce a reduction of cell recruitment allowing for a better control of the disease without significant side effects.
